Sandoz CEO Richard Saynor will outline the company's strategy to seize an unprecedented market opportunity during a presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Speaking on January 13, 2026, Saynor will emphasize Sandoz's progress as a standalone company and its positioning to lead what it calls the 'golden decade' of affordable medicines.
The company reports that reference medicines worth over $600 billion are due to lose exclusivity in the next decade, creating significant opportunities for biosimilar and generic alternatives. Sandoz, as the global leader in affordable medicines, aims to capture a substantial share of this market, which it views as critical for expanding patient access to necessary treatments.
In his prepared remarks, Saynor stated, "I'm proud that we remain consistently on track, and in some cases exceed, on the commitments we have made since becoming an independent company in 2023. As the global leader in the affordable medicines industry, which accounts for 80% of medicines used at just 30% of the total cost, we already have tremendous impact on making healthcare more accessible for all."
Sandoz has established three pillars of global leadership: scale with 1,300 products supplied to over 100 countries, unique positioning as the only 'pure-play' biosimilar and generic company, and a respected leadership team backed by more than 20,000 employees worldwide. The company has delivered on several strategic milestones since becoming independent, including breaking ground on a major new sterile biosimilars production center in Brnik, Slovenia, with a total investment of more than $1.1 billion, and completing the acquisition of Just-Evotec Biologics' site and capabilities in Toulouse, France.
Financially, Sandoz reported 2024 sales of $10 billion, driven by strong double-digit growth in biosimilars. The company maintains a mid-term outlook of mid-single digit annual sales growth to 2028 at constant exchange rates, with core EBITDA margin expansion forecasted to reach 24% to 26% in 2028. This financial strength supports the company's investment plans as it prepares for the coming market opportunity.
The generic opportunity is valued at $340 billion, and Sandoz has a pipeline of over 400 assets targeting nearly two-thirds of this total. The biosimilar opportunity is similarly substantial at $322 billion, with Sandoz targeting approximately 60 percent of this market. The company notes that more than 50 biologics facing loss of exclusivity in the next seven years currently have no biosimilar planned due to high development costs, creating what it calls a 'biosimilar void.'
Sandoz has been leading industry efforts to streamline biosimilar development through regulatory changes that could substantially decrease both cost and time to market without compromising quality, safety, or efficacy. These efforts could help address the biosimilar void and increase patient access to affordable biologic medicines.
The company's strategy includes growing its core generics business with recent key launches across markets including iron ferric, rivaroxaban and enoxaparin sodium in Europe. In biosimilars, its key growth pillar, Sandoz continues to build on its experience as the pioneer and global leader, with a portfolio of 13 molecules in nearly 100 countries and a leading pipeline. The company also maintains a longer-term focus on the emerging GLP-1 market.
Saynor concluded, "We are the global leader in an attractive, growing and system-critical market. We are poised to seize the unprecedented market opportunity over the next decade, in the interests of our shareholders, our customers, our partners and most importantly our patients. If we continue to deliver on our promises the way we have to date, we will lead the way in making the next 10 years the 'golden decade' of affordable healthcare."
Additional information about the presentation is available through the company's website and related investor materials. The original press release can be viewed on NewMediaWire.
